Benzinga
Benzinga
Benzinga
viernes, septiembre 11

Cyclerion Therapeutics Inc Ordinary Shares

CYCNNASDAQ
Trade with Public
Trade with Public
$3.36
-26.39-88.71%
al cierre: Sep 4, 5:00 PM EST
$3.47
-26.28-88.34%
Premercado: Sep 9, 3:00 AM EST
División de acciones: Se espera que Cyclerion Therapeutics Inc Ordinary Shares se divida Wednesday, September 9, 2026 con una proporción de 1:7
Panorámica generalNoticiasPrevisión de beneficiosFinanzasSentimientoPropiedadCompararInforme de acciones

Cyclerion Therapeutics Inc Ordinary Shares Financials

Cyclerion Therapeutics Inc Ordinary Shares (CYCN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Cyclerion Therapeutics Q1 EPS $(0.76) Down From $(0.56) YoY

Cyclerion Therapeutics (NASDAQ:CYCN) reported quarterly losses of $(0.76) per share. This is a 35.71 percent decrease over losses of $(0.56) per share from the same period last year.
Benzinga Newsdesk

PRO
Cyclerion Therapeutics Q2 EPS $(0.11) Up From $(0.53) YoY, Sales $96.00K

Cyclerion Therapeutics (NASDAQ:CYCN) reported quarterly losses of $(0.11) per share. This is a 79.25 percent increase over losses of $(0.53) per share from the same period last year. The company reported $96.00 thousand
Benzinga Newsdesk

Dow Gains 250 Points; Salesforce Shares Jump After Q3 Results

Avi Kapoor

Cyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New Investors

Cyclerion Therapeutics Inc (NASDAQ: CYCN) has agreed to sell two of its assets - zagociguat (formerly CY6463) and CY3018, to a new private company ("NewCo") formed by certain current Cyclerion shareholders and new investors who have agreed to 
Vandana Singh

PRO
Cyclerion Therapeutics Reports Q1 Net Loss Of $(7.0)M Vs $(13.0)M Last Year

Net loss was approximately $(7.0) million for Q1 2023, as compared to approximately $(13.0) million for Q1 2022.
Benzinga Newsdesk

Cyclerion Reports Corporate Update And FY22 Financial Results; Cash, Cash Equivalents, And Restricted Cash Balance On December 31, 2022 Was ~$13.4M

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) today announced corporate updates including advances in its zagociguat (formerly CY6463) mitochondrial disease program.   The Company previously reported clinical data in
Happy Mohamed

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved